情報源 > 更に詳しい情報[069]
参考文献

(1) Burch H, Wartofsky L 1993 Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 14: 747-793.
(2) Tallstedt L, Lundell G 1997 Radioiodine treatment, ablation and ophthalmopathy: A balanced perspective. Thyroid 7: 241-245.
(3) De Groot LJ, Benjasuratwong Y 1996 Evaluation of thyroid ablative therapy for ophthalmopathy of Graves' disease. Orbit 15: 187-196.
(4) De Groot LJ 1997 Radioiodine and the immune system. Thyroid 7: 259-264.
(5) Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A, and the Thyroid Study Group 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 326: 1733-1738.
(6) Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relationship between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338: 73-78.
(7) Mourits MP, Koorneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73: 639-644.
(8) Mourits MP, Prummel MF, Wiersinga WM, Koorneef L 1997 Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 47: 9-14.
(9) Prummel MF, Wiersinga WM, Mourits MP, Koorneef L, Berghout A, van der Gaag R 1990 Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150: 1098-1101.
(10) Sridama V, De Groot LJ 1989 Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 87: 70-73.
(11) Marcocci C, Bartalena L, Bogazzi F, Bruno Bossio G, Pinchera A 1992 Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Thyroid 2: 171-178.
(12) Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves' ophthalmopathy: Reality and perspectives. Endocr Rev 21: 168-199.
(13) Prummel MF, Wiersinga WM, Mourits MP, Koorneef L, Berghout A, van der Gaag R 1989 Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol 121(suppl 2): 185-189.
(14) Volpe R 1994 Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on thyroid cell, modulating thyrocyte-immunocyte signaling: A review. Thyroid 2: 217-223.
(15) Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B, and the Thyroid Study Group 1996 Graves' hyperthyroidism: Treatment with antithyroid drugs, surgery or radioiodine. A prospective, randomized study. J Clin Endocrinol Metab 81: 2986-2993.
(16) Pinchera A, Bartalena L, Marcocci C 1995 Radioiodine may be bad for Graves' ophthalmopathy, but ... J Clin Endocrinol Metab 80: 342-344.
(17) Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A 1989 Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321: 1349-1362.
(18) Winsa B, Rastad J, Akerstrom G, Johansson H, Westermark K, Karlsson FA 1995 Retrospective evaluation of subtotal and total thyroidectomy in Graves' disease with and without endocrine ophthalmopathy. Eur J Endocrinol 132: 406-412.
(19) Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A 1996 Surgical treatment of Graves' disease: Subtotal or total thyroidectomy? Surgery 120: 1020-1025.
(20) Catz B, Perzik SL 1969 Total thyroidectomy in the management of thyrotoxic and euthyroid Graves' disease. Am J Surg 118: 434-439.
(21) Marcocci C, Bartalena L, Pinchera A 1998 Ablative or nonablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 21: 468-471.
(22) Marcocci C, Bruno Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L 1999 The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: A case control study. Clin Endocrinol 51: 503-508.

もどる